Satellite Symposia

SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers
Learn more about the development and emerging clinical role of 177Lu-edotreotide in the treatment of neuroendocrine tumors, focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.

SYMPOSIUM HOST:
Prof. Ken Herrmann, M.D., MBA Nuclear Medicine, University Clinic Essen, Essen, Germany

Speakers:
Prof. Vikas Prasad, M.D., PhD Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, USA
From concept to clinic: The Origins of 177LU-Edotreotide in nets

Dr. Rocío García-Carbonero, M.D., PhD Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
Translating evidence into practise: The role of 177LU-Edotreotide in nets

Prof. Damian Wild, M.D., PhD Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
Exploring the future of the SSTR-Targeting landscape

Moderation:
Prof. Dr. Frederik Giesel, Department of Nuclear Medicine University Hospital Düsseldorf, Germany

Speakers:
Dr. Bastiaan Privé, MD, PhD, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
PSMA-PET/CT in prostate cancer: an overview of the current landscape and ongoing studie

Dr. Mijin Yun, CEO of New Curem, Seoul, South Corea
Clinical Study Results of [¹⁸F]PSMA-1007 in South Korea: Advancing Approval and Diagnostic Innovation

Dr. Pedro José Lopez, Medical Director Nuclear Medicine, Hospital del Mar, Barcelona, Spain
¹⁸F-PSMA-1007 PET Imaging in Primary Prostate Cancer Staging: Case Insights and Handling Tricky Uptakes

Prof. Dr. Wolfgang Schäfer, Chief Physician of the Clinic for Nuclear Medicine Maria Hilf Clinics, Mönchengladbach, Germany
Detecting Biochemical Recurrence with 18F-PSMA-1007: Insights, Case Studies, and Managing Unspecific Bone Uptakes

Prof. Dr. Tobias Maurer, Urologist at Martini Klinik Hamburg, University Hospital Hamburg Eppendorf, Germany
PSMA PET instead of painful biopsies – can we put the urologists out of business?

“From Pan-tumor innovation to theranostic precision : FAP and CAIX case studies “

Introduction and chair:
Agnostic approaches in oncology and drug development: setting the stage: Prof. Italiano

Case study: Fibroblast Activation Protein
Introduction to FAP and diagnostic applications: Dr. Yuriko Mori
FAP-targeted Radiopharmaceutical Therapy: A Promising Avenue in Radiomolecular Oncology : Prof. Dr. Richard P. Baum

Case study: Carbonic Anhydrase IX
Clinical Applications of Carbonic Anhydrase IX : Prof. Daniela Oprea-Lager
Therapeutic potential of CAIX in various types of tumors : Dr. Cristina Suarez

Conclusion : Prof. Italiano

Chair:
Antoine Italiano, Professor of Medical Oncology, Institut Bergonié (University of Bordeaux) & Gustave Roussy (Villejuif), France

Speakers:
Dr. Yuriko Mori, Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Germany
Prof. Dr. Richard P. Baum, CURANOSTICUM Wiesbaden-Frankfurt MVZ, Center for Advanced Radiomolecular Precision Oncology, DKD HELIOS Klinik, Wiesbaden, Germany
Prof. Dr. Daniela Oprea-Lager, Professor as nuclear medicine physician at the  Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands
Dr. Cristina Suárez, Medical oncology department at Vall d’Hebron University Hospital, Barcelona, Spain

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Improving outcomes through early identification and intervention in ATTR-CM

5 min: Welcome and introduction
20 min: ATTR amyloidosis: from clinical suspicion to evidence-based intervention
20 min: Nuclear imaging in ATTR-CM: current practice and future directions
15 min: From imaging to intervention: case-based diagnosis and management of ATTR-CM
5 min: Q&A

Meeting Objectives

• Enhance understanding of both wild-type and hereditary ATTR amyloidosis, with a focus on cardiac involvement, clinical presentation, prognosis and the critical importance of early and accurate detection
• Reinforce the role of nuclear imaging in the evaluation of suspected ATTR-CM, emphasizing its place in the diagnostic pathway and the potential for emerging imaging techniques to enhance detection and disease characterization
• Review the supporting evidence for ATTR-CM management based on robust clinical data and real-world outcomes
• Showcase practical, case-based examples that integrate imaging, genetic testing and multidisciplinary collaboration to optimize patient outcomes

Nuclear Medicine for Alzheimer’s Disease in the Hot Seat Case Conference on Advancing Early Diagnosis With PET Imaging and Biomarkers

Agenda

• 13:00-13:15: Check-In & Hors d’Oeuvres
• 13:15-14:30: In-Person & Virtual Symposium
• Welcome and Introduction
• Foundations of Biomarker-Based Diagnosis in Alzheimer’s Disease
• “Hot Seat” Case Conference: Operationalizing PET Imaging in Alzheimer’s Disease Care
• Take-Home Practice Points and Audience Q&A

Meet Your Presenters
Chair:
Prof. Dr. med. Alexander Drzezga,
Professor and Chair
Department of Nuclear Medicine
University Hospital Cologne
Jülich, Germany
& DZNE Bonn/Köln
& Forschungszentrum Jülich INM-2

Presenters:
Prof. Lyduine Collij,
Assistant Professor
Department of Radiology and Nuclear Medicine
Amsterdam UMC
Amsterdam, Netherlands
Prof. Silvia Daniela Morbelli, MD, PhD,
Full Professor of Nuclear Medicine
Città della Salute e della Scienza di Torino
University of Turin
Turin, Italy

Summary
Recent global regulatory approvals and upcoming pending decisions for amyloid-targeting therapies (ATTs) in Alzheimer’s disease (AD) have intensified the need for accurate and timely identification of amyloid pathology. As amyloid PET becomes central to the diagnostic workup for early symptomatic AD, nuclear medicine physicians are assuming a more prominent role within the multidisciplinary care team, and a substantial increase in demand for PET imaging is expected.

Join PeerView at the 2025 European Association of Nuclear Medicine Congress and meet this demand with confidence! In this live symposium, experts on the role of nuclear medicine in AD will provide guidance on utilizing validated and emerging neuroimaging biomarkers and quantitative measures in clinical practice to facilitate early diagnosis of AD. Through a blend of concise presentations and case-based discussions, learners will receive a practical framework for incorporating cutting-edge strategies in routine patient care, determining eligibility for treatment with ATTs, and effectively communicating PET imaging findings within the care team. Register now to learn how you can enhance diagnostic precision and optimize therapeutic decision-making in early symptomatic AD!

This CME/EBAC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Lilly.

Check in today to join us at PeerView.com/25AD-Live!

Advancing radiotheranostics: precision medicine of today and the path forward
Join us for a focused satellite symposium exploring the evolving role of radiotheranostics in modern patient care. The session will highlight current clinical applications, breakthroughs in targeted diagnostics and therapies, and the strategic steps needed to integrate radiotheranostics into broader precision medicine frameworks. From today’s innovations to tomorrow’s possibilities, discover how this transformative approach is reshaping healthcare.

Chairperson:
Dr. Ilya Gipp, Medical Director, GE HealthCare

Speakers:
Prof. Gustav von Schulthess, Chairman of the Department of Medical Radiology at University Hospital Zurich
Prof. Lisa Rowley, head of nuclear medicine, University Hospital Coventry & Warwickshire
Prof. Diego Cecchin, head of nuclear medicine, Padova University Hospital.

Can Nuclear Medicine and Referring Clinicians bridge the PSMA PET access gap?

Summary:
The PSMA PET access gaps limit patient care and hinders Nuclear Medicine’s rise in healthcare. EANM25 gathers the Medical Community to address this issue, promoting a tighter collaboration with Referring Clinicians to ensure fair access and enable the field’s next breakthroughs.

Speakers:
Prof. Dr. Vineet Prakash, Nuclear Medicine Physician, Department of Nuclear Medicine, Royal Surrey Hospital, UK
European overview of the PSMA PET accessibility challenges: the Nuclear Medicine Physician’s perspective

Ass. Prof. Dr. Juan Gomez Rivas, Urologist, Department of Urology, Hospital Clínico San Carlos, Madrid, Spain
Enhancing Patient Care through Expanded PSMA PET Access: the Urologist’s Perspective

Dr. Jean-Emmanuel Filmont, Nuclear Medicine Physician, Department of Nuclear Medicine, American Hospital, Paris, France
Achieving full PSMA PET Adoption: Experience and lessons from a tight Urologist-Nuclear Medicine Collaboration

Seeing More: Transforming Care with Molecular Imaging
Molecular imaging (MI) is transforming care by enabling practitioners to see more. Discover how next-generation MI technologies are redefining and advancing precision medicine outcomes. Experts will share their opinions and experience on how high-resolution scanning, low-count high-quality imaging, and advanced quantitative analytics unlock new clinical potential. Join us to gain deeper insights across patient populations through enhanced detection capabilities, and translating the findings into actionable treatment monitoring and optimized therapeutic pathways.

Moderator:
Stewart Young, Lead Research Collaboration Scientist, United Imaging Healthcare Europe

Speakers:
Dr. Thomas Mognetti, MD, Head of Nuclear Medicine Department, Centre Léon Bérard, Lyon, France
Low-dose Imaging – Initial Clinical Experience using uMI Panorama PET/CT

Prof. Dr. Roger Gunn, PhD, Chief Science Officer, Xing Imaging, New Haven, USA
High-resolution Brain PET/CT at Xing Imaging using uNeuroEXPLORER

Dr. Claudio Rossetti, MD, Director of Nuclear Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy
Beyond Static: First Clinical Experience with Dynamic LAFOV PET at Niguarda Milan

Prof. Dr. Frank M. Bengel, MD, Hannover, Germany
Dynamic by Design – Where do we go with LAFOV PET?

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.